AGC Biologics

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Manufacturing

AGC Biologics partners with Asahi Kasei Pharma Corporation on antibody project

Asahi has been chosen by AGC Biologics for its monoclonal antibody development and manufacturing experience to perform process transfer, process optimisation, and clinical manufacturing of the Asahi Kasei Pharma drug substance
Manufacturing

AGC Biologics invests in viral vector suspension production capacity

The company has announced the expansion that more than doubles the site's viral vector capacity
Manufacturing

AGC to support Pfizer-BioNTech Omicron vaccine

Plasmid DNA from AGC is already supplied as a starting material for the companies' COVID-19 vaccine
Manufacturing

AGC expands plasmid DNA capacity in Germany

ACG’s Heidelberg site has completed a pDNA manufacturing process improvement project that expands the service in hosts and plasmids
Manufacturing

CALY-002 antibody: AGC and Calypso team up on manufacture process

Calypso’s pipeline antibody project will have its process and cGMP manufacture developed by AGC
Subscribe now